Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cardiff Oncology Inc (CRDF)

Cardiff Oncology Inc (CRDF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 142,132
  • Shares Outstanding, K 67,361
  • Annual Sales, $ 680 K
  • Annual Income, $ -45,430 K
  • EBIT $ -54 M
  • EBITDA $ -54 M
  • 60-Month Beta 1.35
  • Price/Sales 213.03
  • Price/Cash Flow N/A
  • Price/Book 2.98

Options Overview Details

View History
  • Implied Volatility 164.37% (-42.02%)
  • Historical Volatility 53.82%
  • IV Percentile 67%
  • IV Rank 25.45%
  • IV High 452.39% on 04/23/25
  • IV Low 66.07% on 08/13/25
  • Expected Move (DTE 12) 0.26 (12.09%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 49
  • Volume Avg (30-Day) 714
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 21,212
  • Open Int (30-Day) 25,540
  • Expected Range 1.86 to 2.37

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.18
  • Number of Estimates 4
  • High Estimate -0.16
  • Low Estimate -0.20
  • Prior Year -0.21
  • Growth Rate Est. (year over year) +14.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.90 +11.05%
on 11/21/25
2.37 -10.97%
on 11/26/25
-0.13 (-5.80%)
since 11/05/25
3-Month
1.90 +11.05%
on 11/21/25
2.47 -14.57%
on 10/09/25
-0.06 (-2.76%)
since 09/05/25
52-Week
1.90 +11.05%
on 11/21/25
5.64 -62.59%
on 12/17/24
-0.23 (-9.83%)
since 12/05/24

Most Recent Stories

More News
Cardiff Oncology to Present at the Piper Sandler 37th Annual Healthcare Conference

SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers,...

CRDF : 2.11 (-2.31%)
Cardiff Oncology: Q3 Earnings Snapshot

Cardiff Oncology: Q3 Earnings Snapshot

CRDF : 2.11 (-2.31%)
Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update

– Announced positive data from the ongoing Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer – – Expects...

CRDF : 2.11 (-2.31%)
Cardiff Oncology to Participate in Two Upcoming Investor Conferences

SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers,...

CRDF : 2.11 (-2.31%)
Cardiff Oncology to Participate in Two Upcoming Investor Conferences

SAN DIEGO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers,...

CRDF : 2.11 (-2.31%)
Cardiff Oncology to Participate in Three Upcoming Investor Conferences

SAN DIEGO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers,...

CRDF : 2.11 (-2.31%)
Cardiff Oncology: Q2 Earnings Snapshot

Cardiff Oncology: Q2 Earnings Snapshot

CRDF : 2.11 (-2.31%)
Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004)

– Trial demonstrates 49% confirmed ORR in the 30mg onvansertib dose arm versus 30% confirmed ORR in the control arm in intent-to-treat population (N=110) – – Early PFS data show a trend favoring...

CRDF : 2.11 (-2.31%)
Cardiff Oncology Reports Second Quarter 2025 Results and Provides Business Update

- Appointed Dr. Roger Sidhu as Chief Medical Officer - - Completed enrollment in randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated...

CRDF : 2.11 (-2.31%)
Emerging Oncology Breakthroughs Signal Opportunity Despite Research Funding Crunch

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – Budget cuts are on the horizon for funding scientific research, and if supported by Congress, the development...

ONCY : 0.9921 (+1.16%)
CTMX : 3.95 (-3.19%)
NUVB : 8.55 (+2.89%)
IMRX : 6.40 (-4.33%)
ONC.TO : 1.42 (+2.16%)
CRDF : 2.11 (-2.31%)

Business Summary

Cardiff Oncology Inc. is a clinical-stage biotechnology company. It engages in developing treatment for cancer patients. The company's product pipeline consists of a Phase 1b/2 study of onvansertib in combination with FOLFIRI/Avastin(R) in KRAS-mutated metastatic colorectal cancer; a Phase 2 study of...

See More

Key Turning Points

3rd Resistance Point 2.30
2nd Resistance Point 2.26
1st Resistance Point 2.18
Last Price 2.11
1st Support Level 2.06
2nd Support Level 2.02
3rd Support Level 1.94

See More

52-Week High 5.64
Fibonacci 61.8% 4.21
Fibonacci 50% 3.77
Fibonacci 38.2% 3.33
Last Price 2.11
52-Week Low 1.90

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar